Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Akebia Therapeutics (AKBA) Accumulated Depreciation & Amortization (2016 - 2022)

Akebia Therapeutics has reported Accumulated Depreciation & Amortization over the past 8 years, most recently at $1.7 million for Q4 2022.

  • Quarterly Accumulated Depreciation & Amortization fell 14.17% to $1.7 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Dec 2022, down 14.17% year-over-year, with the annual reading at $1.7 million for FY2022, 14.17% down from the prior year.
  • Accumulated Depreciation & Amortization was $1.7 million for Q4 2022 at Akebia Therapeutics, down from $1.9 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $5.2 million in Q3 2020 and troughed at $899000.0 in Q4 2018.
  • The 5-year median for Accumulated Depreciation & Amortization is $2.2 million (2019), against an average of $2.6 million.
  • Year-over-year, Accumulated Depreciation & Amortization dropped 15.11% in 2018 and then soared 149.72% in 2019.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $899000.0 in 2018, then soared by 149.72% to $2.2 million in 2019, then fell by 7.57% to $2.1 million in 2020, then fell by 7.13% to $1.9 million in 2021, then fell by 14.17% to $1.7 million in 2022.
  • Per Business Quant, the three most recent readings for AKBA's Accumulated Depreciation & Amortization are $1.7 million (Q4 2022), $1.9 million (Q4 2021), and $2.1 million (Q4 2020).